





Fig. 1






Fig. 3B




Fig. 3A





Fig. 3C

		EC50s (mg/mL)									
	clone 2	clone 5	clone 13	clone 16	clone 17	clone 20	clone 25	clone 54			
human	0.15	0.12	0.07	0.07	0.06	0.24	0.14	0.11			
mouse	0.25	5.39	0.08	0.08			0.24				
cyno	0.32	1.17	0.10	0.10			0.19	11.44			

Fig. 3D

FIG. 4






Fig. 5B




Fig. 5A





Fig. 6

anti-TIGIT Antibody-Mediated Luciferase Induction



Correlation Plot: TIGIT/CD155
Blockade Bioassay vs TIGIT-Fc Affinity




Fig. 7A




Fig. 7B




Fig. 8

FIG. 9B




FIG. 9A




FIG. 9C




FIG. 9D

EC50s (µg/mL)			
	c13 hlgG1	c13 mlgG1	c13 mlgG2a
human	0.09	0.05	0.04
mouse	0.10	0.06	0.05
cyno	0.13	0.07	0.07

FIG. 9F




FIG. 9E




FIG. 9G




FIG. 9H





FIG. 10A



Balb/c female mice
CT26 (3E+05 cells/mouse) s.c. inoculation 28Oct2016
aTIGIT: biwk x 3 IP dosing from day 1
13-1 = mlgG1 chimera of clone 13
13-2 = mlgG2a chimera of clone 13
aPD-1: biwk x 2 IP dosing from day 1
Study day 1 = day 7 after tumor inoculation
Charles River Laboratories Study # CT26-e323

FIG. 10B




FIG. 10C




FIG. 10D





FIG. 10E






FIG. 10G




FIG. 10H




FIG. 10I




FIG. 10J





FIG. 10K






Fig. 11






Fig. 11 (cont.)

*Fig. 11 (cont.)*

	mlgG2a	mlgG2a AFUCOS.	mlgG2a LALA-PG
KD (nM)	33.4	2.37	3330
KD Std. Error	1.1	0.21	120
Bmax	16720	19270	17045

Fig. 12




Fig. 13




Fig. 14





Fig. 15

**Fig. 16**




Fig. 17

Fig. 18A




Fig. 18B





Fig. 18C



ADCC of A549 targets




Fig. 19




CMV Induced IFN γ Production

Fig. 20

CMV Induced IFN γ Production**Fig. 21****Mixed Lymphocyte Reaction IL2 Production****Fig. 22**





Fig. 23

37/63

*Fig. 23 (cont.)*





Fig. 24

*Fig. 24 (cont.)*

40/63





Fig. 25

*Fig. 25 (cont.)*





Fig. 26A

*Fig. 26A (cont.)*





Fig. 26B

*Fig. 26B (cont.)*




Fig. 27




Fig. 28

EMT6






Fig. 29A


E0771
E0771 5 mg/kg TIGIT




E0771 Untreated



1 mg/kg SEA TIGIT



0.1 mg/kg SEA TIGIT



5 mg/kg SEA TIGIT




Fig. 29B




Fig. 29C

51/63




Fig. 30




Fig. 31




Fig. 32

54/63

- * Untreated
- OVA/CFA
- OVA/CFA WT TIGIT
- △ OVA/CFA SEA TIGIT
- ◇ OVA/CFA LALA TIGIT

IFN γ

IL5




Fig. 33

- * Untreated
- OVA/CFA
- OVA/CFA WT TIGIT
- △ OVA/CFA SEA TIGIT
- ◇ OVA/CFA LALA TIGIT




Fig. 33 (cont.)




Fig. 34




Fig. 35




Fig. 36




Fig. 37




Fig. 37 (cont.)




Fig. 38B




Fig. 38A




Fig. 39A




Fig. 39B




Fig. 39C




Fig. 39D




Fig. 40




Fig. 41